Yahoo
XETRA - Delayed Quote EUR

Biofrontera AG (B8FK.DE)

2.4200 -0.0400 (-1.63%)
At close: 5:35:36 PM GMT+2
Chart Range Bar
Loading chart for B8FK.DE
  • Previous Close 2.4600
  • Open 2.4700
  • Bid 2.3600 x --
  • Ask 2.4800 x --
  • Day's Range 2.3600 - 2.4800
  • 52 Week Range 2.2100 - 2.9600
  • Volume 2,573
  • Avg. Volume 1,046
  • Market Cap (intraday) 14.706M
  • Beta (5Y Monthly) -0.23
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0900
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. In addition, the company focus on photodynamic therapy (PDT) for the treatment of actinic keratosis and keratinocyte skin cancers, including basal cell carcinoma. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

www.biofrontera.com

69

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 8/13/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

B8FK.DE
0.82%
DAX P (^GDAXI)
7.39%

1-Year Return

B8FK.DE
9.36%
DAX P (^GDAXI)
8.74%

3-Year Return

B8FK.DE
82.85%
DAX P (^GDAXI)
66.12%

5-Year Return

B8FK.DE
94.94%
DAX P (^GDAXI)
64.61%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY22
Revenue 8.51M
Earnings -8.64M

Q3

FY21

Q4

FY21

Q1

FY22

Q2

FY22

-20M
0
20M
40M

Statistics

View More

Valuation Measures

Annual
As of 8/10/2026
  • Market Cap

    15.62M

  • Enterprise Value

    11.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.14

  • Price/Book (mrq)

    0.91

  • Enterprise Value/Revenue

    0.81

  • Enterprise Value/EBITDA

    18.71

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.92%

  • Return on Assets (ttm)

    -1.96%

  • Return on Equity (ttm)

    -36.44%

  • Revenue (ttm)

    13.63M

  • Net Income Avi to Common (ttm)

    -6.68M

  • Diluted EPS (ttm)

    -1.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.64M

  • Total Debt/Equity (mrq)

    11.06%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Mobilize your Website
View Site in Mobile | Classic
Share by: